Screener
Ultragenyx Pharmaceutical RARE Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $39 | $31 |
| Accrued liabilities | 221 | 265 |
| Liabilities for sales of future royalties | 76 | 69 |
| Other liabilities | 15 | 19 |
| Total current liabilities | 351 | 384 |
| Deferred tax liabilities | 30 | 30 |
| Liabilities for sales of future royalties | 1,126 | 1,147 |
| Other liabilities | 41 | 44 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's accrued expenses?
- Ultragenyx Pharmaceutical (RARE) reported accrued expenses of $15M in Q2 2026.
- How has Ultragenyx Pharmaceutical's accrued expenses changed year-over-year?
- Ultragenyx Pharmaceutical's accrued expenses increased by 481.2% year-over-year, from $2.58M to $15M.
- What is the long-term trend for Ultragenyx Pharmaceutical's accrued expenses?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's accrued expenses has grown at a -29.4% compound annual growth rate (CAGR), from $108.49M to $19M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Ultragenyx Pharmaceutical's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude